Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

v3.10.0.1
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
Common Stock
Preferred Stock
Additional Paid in Capital
Accumulated Deficit
Stockholders' Deficit - TransBiotec Inc.
Total
Noncontrolling Interest
Beginning balance, Shares at Dec. 31, 2014 60,251,068          
Beginning balance, Amount at Dec. 31, 2014 $ 602 $ 14,353,628 $ (16,468,956) $ (2,114,726) $ (2,154,525) $ (39,799)
Common Stock issued for cash, Shares 5,000,000          
Common Stock issued for cash, Amount $ 50 24,950 25,000 25,000
Common Stock issued to settle accounts payable, Shares 2,500,000          
Common Stock issued to settle accounts payable, Amount $ 25 9,725 9,750 9,750
Paid in capital - beneficial conversion feature (21,500) (21,500) (21,500)
Paid in capital - Stock Warrants Amortization (7,512) (7,512) (7,512)
Paid in capital - Gain on related party debt conversion (83,823) (83,823) (83,823)
Paid in capital - Reclassification of common share equivalents to derivative liabilities (180,038) (180,038) (180,038)
Share exchange - noncontrolling interest (4,102) (4,102)
Net loss for the year (595,130) (595,130) (595,130)
Ending balance, Shares at Dec. 31, 2016 67,751,068          
Ending balance, Amount at Dec. 31, 2016 $ 677 14,095,430 (17,064,086) (2,967,979) (3,011,880) (43,901)
Common Stock issued for cash, Shares 7,202,679          
Common Stock issued for cash, Amount $ 72 60,128 60,200 60,200
Common Stock issued to settle accounts payable, Shares 2,151,417          
Common Stock issued to settle accounts payable, Amount $ 23 11,493 11,516 11,516
Common Stock issued to settle non related party debt, Shares 55,834          
Common Stock issued to settle non related party debt, Amount $ 1 18,066 18,067 18,067
Common Stock issued due to options exercise, Shares 32,248,932          
Common Stock issued due to options exercise, Amount $ 323 112,548 112,871 112,871
Preferred Stock issued for debt, Shares 1,388,575          
Preferred Stock issued for debt, Amount $ 14 14 14
Paid in capital - Stock Warrants Amortization 86,955 86,955 86,955
Paid in capital - Gain on related party debt conversion 182,111 182,111 182,111
Paid in capital - Reclassification of common share equivalents to derivative liabilities (199,919) (199,919) (199,919)
Paid in capital - Fair Value of Unamortized Stock Warrants 19,969 19,969 19,969
Paid in capital - Fair Value of Stock Compensation 6,290 6,290 6,290
Paid in capital - Reclassification of derivative liabilities to common share equivalents 391,980 391,980 391,980
Share exchange - noncontrolling interest (3,226) (3,226)
Net loss for the year (639,085) (639,085) (639,085)
Ending balance, Shares at Dec. 31, 2017 109,409,930 1,388,575          
Ending balance, Amount at Dec. 31, 2017 $ 1,096 $ 14 $ 14,785,051 $ (17,703,171) $ (2,917,010) $ (2,964,137) $ (47,127)